summary
Introduced
03/09/2022
03/09/2022
In Committee
03/10/2022
03/10/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
AI Summary
This bill amends the Federal Food, Drug, and Cosmetic Act to require holders of approved applications for biological products, such as pharmaceuticals derived from living organisms, to promptly report on the marketing status of their products. The bill specifically requires these application holders to review and submit information on the availability of their biological products listed in the "Purple Book," which is a publication that contains information about approved biological products. The bill also establishes a one-time reporting requirement for these application holders to notify the Secretary of Health and Human Services whether their biological products are available for sale or have been withdrawn from the market.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (2)
Last Action
Referred to the Subcommittee on Health. (on 03/10/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/7035/all-info |
| BillText | https://www.congress.gov/117/bills/hr7035/BILLS-117hr7035ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr7035/BILLS-117hr7035ih.pdf.pdf |
Loading...